Send to

Choose Destination
Front Immunol. 2018 Jun 28;9:1480. doi: 10.3389/fimmu.2018.01480. eCollection 2018.

Hepatitis C Vaccines, Antibodies, and T Cells.

Author information

Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada.
Département de médecine, Faculté de médecine, Université de Montréal, Montréal, QC, Canada.


The development of vaccines that protect against persistent hepatitis C virus (HCV) infection remain a public health priority. The broad use of highly effective direct-acting antivirals (DAAs) is unlikely to achieve HCV elimination without vaccines that can limit viral transmission. Two vaccines targeting either the antibody or the T cell response are currently in preclinical or clinical trials. Next-generation vaccines will likely involve a combination of these two strategies. This review summarizes the state of knowledge about the immune protective role of HCV-specific antibodies and T cells and the current vaccine strategies. In addition, it discusses the potential efficacy of vaccination in DAA-cured individuals. Finally, it summarizes the challenges to vaccine development and the collaborative efforts required to overcome them.


T cells; antibodies; hepatitis C; reinfection; vaccines

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center